evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,703 questions · 15,007 findings · 1,416 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 2,881 · 19.2%GRADE not reported 1,551 · 10.3%Very low 3,111 · 20.7%Low 3,881 · 25.9%Moderate 2,669 · 17.8%High 914 · 6.1%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Live zoster vaccine vs placebo

Cumulative incidence of herpes zoster, 3.1 years · healthy older adults aged ≥ 60 years

Live zoster vaccine probably leads to lower cumulative incidence of herpes zoster, 3.1 years compared with placebo (moderate certainty).

1 finding from 1 review

Recombinant zoster vaccine vs placebo

Participants with adverse events ‐ serious adverse events Clinical or laboratory criteria · healthy older adults aged ≥ 60 years

Recombinant zoster vaccine showed no clear difference in participants with adverse events ‐ serious adverse eventsClinical or… compared with placebo (moderate certainty).

1 finding from 1 review

Recombinant zoster vaccine vs placebo

Adverse effects of any severity (systemic symptoms) · healthy older adults aged ≥ 60 years

Recombinant zoster vaccine probably leads to higher participants with adverse events ‐ any systemic symptomClinical… compared with placebo (moderate certainty).

1 finding from 1 review

Recombinant zoster vaccine vs placebo

Participants with adverse events ‐ potential immune‐mediated disease Clinical or laboratory criteria · healthy older adults aged ≥ 60 years

Recombinant zoster vaccine showed no clear difference in participants with adverse events ‐ potential immune‐mediated… compared with placebo (moderate certainty).

1 finding from 1 review

Recombinant zoster vaccine vs placebo

Participants with adverse events ‐ any local symptom Clinical criteria · healthy older adults aged ≥ 60 years

Recombinant zoster vaccine probably leads to higher participants with adverse events ‐ any local symptomClinical criteria compared with placebo (moderate certainty).

1 finding from 1 review

Recombinant zoster vaccine vs placebo

Dropouts ‐ did not receive second dose Clinical or laboratory criteria · healthy older adults aged ≥ 60 years

Recombinant zoster vaccine probably leads to higher dropouts ‐ did not receive second doseClinical or laboratory criteria compared with placebo (moderate certainty).

1 finding from 1 review

Live zoster vaccine vs placebo

Participants with adverse events Clinical or laboratory criteria · healthy older adults aged ≥ 60 years

Live zoster vaccine probably leads to higher participants with adverse eventsClinical or laboratory criteria compared with placebo (moderate certainty).

1 finding from 1 review

Live zoster vaccine vs placebo

Participants with adverse events: 1 or more serious adverse events regardless of type of storage of the vaccine Clinical or laboratory criteria · healthy older adults aged ≥ 60 years

Live zoster vaccine showed no clear difference in participants with adverse events: 1 or more serious adverse events… compared with placebo (moderate certainty).

1 finding from 1 review

Live zoster vaccine vs placebo

Systemic adverse events at · healthy older adults aged ≥ 60 years

Live zoster vaccine showed no clear difference in participants with adverse events ‐ systemic adverse eventsClinical… compared with placebo (moderate certainty).

1 finding from 1 review

Live zoster vaccine vs placebo

Participants with adverse events ‐ injection site adverse events Clinical criteria · healthy older adults aged ≥ 60 years

Live zoster vaccine probably leads to higher participants with adverse events ‐ injection site adverse… compared with placebo (moderate certainty).

1 finding from 1 review

Live zoster vaccine vs placebo

Dropouts Clinical or laboratory criteria · healthy older adults aged ≥ 60 years

Live zoster vaccine showed no clear difference in dropoutsClinical or laboratory criteria compared with placebo (moderate certainty).

1 finding from 1 review

Recombinant zoster vaccine vs placebo

Cumulative incidence of herpes zoster at least 3.2 years · healthy older adults aged ≥ 60 years

Recombinant zoster vaccine probably leads to lower cumulative incidence of herpes zoster at least 3.2 years compared with placebo (moderate certainty).

1 finding from 1 review

Recombinant zoster vaccine vs placebo

Participants with adverse events ‐ death Clinical criteria · healthy older adults aged ≥ 60 years

Recombinant zoster vaccine showed no clear difference in participants with adverse events ‐ deathClinical criteria compared with placebo (moderate certainty).

1 finding from 1 review

Immunoglobulin vs placebo

Mortality (any cause during hospitalisation or · children with respiratory syncytial virus infection

It is very uncertain whether summary of findings table ‐ Immunoglobulins changes mortality (any cause during hospitalisation or compared with placebo (very low certainty).

1 finding from 1 review